Guidance for Optimal Site Selection of a Leadless LV Endocardial Electrode Improves Acute Hemodynamic Response and Chronic Remodeling by Sieniewicz, Benjamin J. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.jacep.2018.03.011
Document Version
Version created as part of publication process; publisher's layout; not normally made publicly available
Link to publication record in King's Research Portal
Citation for published version (APA):
Sieniewicz, B. J., Behar, J. M., Gould, J., Claridge, S., Porter, B., Sidhu, B. S., ... Rinaldi, C. A. (2018). Guidance
for Optimal Site Selection of a Leadless LV Endocardial Electrode Improves Acute Hemodynamic Response and
Chronic Remodeling. JACC: Clinical Electrophysiology. DOI: 10.1016/j.jacep.2018.03.011
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 14. May. 2018
J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y VO L . - , N O . - , 2 0 1 8
ª 2 0 1 8 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F OU N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .Guidance for Optimal Site Selection of a
Leadless LV Endocardial Electrode
Improves Acute Hemodynamic Response
and Chronic Remodeling
Benjamin J. Sieniewicz, MBCHB FHEA,a,b Jonathan M. Behar, MBBS,a,b Justin Gould, MBBS,a,b
Simon Claridge, LLB MBBS,a,b Bradley Porter, MBBS,a,b Baldeep S. Sidhu, BM,a,b Steve Niederer, PHD,a
Tim R. Betts, MBCHB FRCP MD,c David Webster,c Simon James, MBCHB HRUK,d Andrew J. Turley, MBCHB,d
Christopher A. Rinaldi, MD, FHRSa,b
ABSTRACTISS
Fro
De
De
dC
Kin
Ab
fel
fun
ack
con
spe
rep
All
ins
vis
MaOBJECTIVES This study hypothesized that guided implants, in which the optimal left ventricular endocardial (LVENDO)
pacing location was identiﬁed and targeted, would improve acute markers of contractility and chronic markers of cardiac
resynchronization (CRT) response.
BACKGROUND Biventricular endocardial (BiVENDO) pacing may offer a potential beneﬁt over standard CRT; however,
the optimal LVENDO pacing site is highly variable. Indiscriminately delivered BiVENDO pacing is associated with a reverse
remodeling response rate of between 40% and 60%.
METHODS Registry of centers implanting a wireless, LVENDO pacing system (WiSE-CRT System, EBR Systems, Sunny-
vale, California); John Radcliffe Hospital (Oxford, United Kingdom), Guy’s and St. Thomas’ Hospital (London, United
Kingdom), and The James Cook University Hospital (Middlesbrough, United Kingdom). Centers used a combination of
preprocedural imaging and electroanatomical mapping the identify the optimal LVENDO site.
RESULTS A total of 26 patients across the 3 centers underwent a guided implant. Patients were predominantly male
with a mean age of 68.8  8.4 years, the mean LV ejection fraction was 34.2%  7.8%. The mean QRS duration was
163.8  26.7 ms, and 30.8% of patients had an ischemic etiology. It proved technically feasible to selectively target and
deploy the pacing electrode in a chosen endocardial segment in almost all cases, with a similar complication rate to that
observed during indiscriminate BiVENDO. Ninety percent of patients met the deﬁnition of echocardiographic responder.
Reverse remodeling was observed in 71%.
CONCLUSIONS Guided endocardial implants were associated with a higher degree of chronic LV remodeling compared
with historical nonguided approaches. (J Am Coll Cardiol EP 2018;-:-–-) © 2018 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2405-500X https://doi.org/10.1016/j.jacep.2018.03.011
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ABBR EV I A T I ON S
AND ACRONYMS
AHR = Acute hemodynamic
response
BiVENDO = biventricular
endocardial
CMR = cardiac magnetic
resonance imaging
CRT = cardiac
resynchronization therapy
EAM = electroanatomical
mapping
LV = left ventricular
LVEF = left ventricular ejection
fraction
LVENDO = left ventricular
endocardial
Q-LV = interval between the
onset of the QRS complex on
the surface electrocardiogram
to the ﬁrst large positive or
negative peak of the LV
electrogram during a cardiac
cycle
QRSd = QRS duration
US = ultrasound
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2S igniﬁcant numbers of patients fail torespond to cardiac resynchronization(CRT) when it is delivered through an
epicardial left ventricular (LV) lead placed
via the coronary sinus (1–3). Furthermore,
technical and anatomical limitations mean it
is not always possible to implant an LV lead
(4) and patients upgrading from a preexisting
pacing system may have central venous ste-
noses preventing transvenous LV lead
implantation (5). To overcome these chal-
lenges, novel methods of CRT delivery have
been developed, including LV endocardial
(LVENDO) stimulation (6,7). Chronic LVENDO
pacing was initially delivered via trans-
septal pacing leads, mandating lifelong anti-
coagulation, but the introduction of new
wireless technology may increase the use of
LVENDO pacing and avoid anticoagulation
(8,9).
The optimal LVENDO pacing location ex-
hibits marked variability in ischemic (10) and
nonischemic patients (11–13), with indiscrim-
inate LVENDO CRT being inferior to traditional
transvenous epicardial CRT (6). Avoidingscarred tissue while targeting viable, late-activating
sites may improve conventional CRT response (14–
16). Targeting the site of latest mechanical activation
using speckle-tracking in the Targeted Left Ventricular
Lead Placement to Guide Cardiac Resynchronization
Therapy study improved the reverse remodeling rate
to >70% (17). Alternative strategies include targeting
the site of latest electrical activation, using the interval
between the onset of the QRS complex on the surface
electrocardiogram to the ﬁrst large positive or negative
peak of the LV electrogram during a cardiac cycle
(Q-LV) (16) or using cardiac magnetic resonance (CMR)
to identify late-activating, viable tissue (18).
We hypothesized that identiﬁcation of the optimal
LVENDO location for a wireless LV pacing electrode
would result in improved acute hemodynamic
response and chronic remodeling. We performed
LENDO pacing using the WiSE-CRT wireless pacing
system (WiSE-CRT System, EBR Systems, Sunnyvale,
California) in conjunction with guidance to identify
late-activating, viable LVENDO segments and
measured acute markers of contractility and chronic
markers of CRT response (reverse remodeling).
METHODS
Data were collected from 3 centers implanting the
WiSE-CRT system. This co-implant system uses ul-
trasound (US) energy to activate a small leadlesspacing electrode that is deployed transarterially via a
retrograde transaortic approach in the LVENDO cavity.
The US array, implanted subcutaneously, is triggered
by the implanted pacemaker or transvenous deﬁbril-
lator. Patients studied were part of the WiCS Post
Market Surveillance Registry (Clinical trial study
number NCT02610673), and all patients gave full
written consent to participate in the study. The
centers were the John Radcliffe Hospital, Oxford
University Hospitals National Health Service (NHS)
Foundation Trust (Oxford, United Kingdom), Guy’s
and St Thomas’ NHS Foundation Trust (London,
United Kingdom), and The James Cook University
Hospital, South Tees Hospitals NHS Foundation Trust
(Middlesbrough, United Kingdom).
LVENDO GUIDANCE. At each center, a combination of
either preprocedural imaging and/or electro-
anatomical mapping (EAM) was used to identify the
optimal LVENDO pacing site.
Echocardiographic-guided approach. This approach was
undertaken at the James Cook University Hospital.
Echocardiography using Speckle-tracking 2-
dimensional radial strain analysis was used to iden-
tify and target the latest mechanically activated LV
segment using multisegment models, as described
previously (19). Regions of scar were deﬁned as
segments <0.5-mm thick and displaying abnormal
increase in acoustic reﬂection. In addition, any
myocardium that exhibited low-amplitude strain
curves and a peak radial strain <16.5% was deﬁned as
scar (20,21). During LVENDO implantation, the LV free
wall was visualized using ﬂuoroscopy and was sub-
divided into 4 segments according to coronary
venous anatomy; anterolateral, lateral, posterolat-
eral, and posterior, as previously described (19). The
electrode could then be implanted into the target
segment.
Electr i ca l latency (Q-LV) . This work was under-
taken at the John Radcliffe Hospital. Electrical la-
tency was assessed using the WiSE-CRT delivery
catheter. A minimum of 3 sites were tested. Two
indices of electrical latency were used to identify the
optimal pacing site; the Q-LV activation time (16) and
the Q-LV/QRS ratio (7,15). Sites with a Q-LV <100 ms
were excluded. The optimal target was the site that
displayed the latest Q-LV during right ventricular
pacing and a Q-LV/QRS ratio >0.66. Viability was
assessed by excluding any sites with a pacing capture
threshold >2 V.
EAM and CMR. This work was undertaken at Guy’s
and St. Thomas’ NHS Foundation Trust. Patients were
implanted using a hybrid approach of EAM and,
where possible, CMR imaging, which had been per-
formed before implantation of the co-implant device.
TABLE 1 Patient Demographics (n ¼ 26)
Mean  SD or
Numbers (%)
Patients 26
Age (y) 68.8  8.4
Male (%) 22 (84.6)
LVEF (%) 34.2%  7.8
NYHA 2.6  0.5
QRS duration (ms) 163.8  26.7
QRS morphology
RV paced 24 (92)
LBBB 2 (8)
Etiology
ICM (%) 8 (30.8)
Indication
Difﬁcult CS anatomy/access 14 (53.8)
Upgrades
High-risk upgrade 7 (26.9)
Prior infection/extraction 3 (11.5)
Failure to respond to BiV EPI 2 (8.0)
Guidance technique
Echocardiographic 9 (34.6)
Electrical latency 10 (38.%)
CMR and EAM 7 (26.9)
BiV ¼ biventricular; CMR ¼ cardiac magnetic resonance; CS ¼ coronary sinus;
EAM ¼ electro-anatomical mapping; EPI ¼ epicardial; ICM ¼ ischemic cardiomy-
opathy; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection fraction;
NYHA ¼ New York Heart Association; RV ¼ right ventricular.
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3This technique allowed the identiﬁcation of areas
exhibiting late electrical activation (bipolar activation
map) and areas of low voltage (bipolar scar map) us-
ing CARTO 3 (Biosense Webster, Diamond Bar, Cali-
fornia), as previously described (22). When available,
prior CMR data were also analyzed, allowing the
identiﬁcation of both late mechanically activated
tissue and via analysis of late gadolinium enhance-
ment imaging, areas of scared or ﬁbrotic myocardium
(Siemens Magnetom Aera 1.5-T magnetic resonance
imaging scanner, Siemens Healthcare, Erlangen,
Germany).
INCLUSION CRITERIA. The WiSE-CRT pacing system
is CE marked for 3 indications (9). Patients classiﬁed
as nonresponders to conventional CRT, those in
whom LV lead deployment is not possible (because of
anatomical constraints, high capture thresholds, or
phrenic nerve stimulation), and those undergoing
CRT upgrade where implanting an LV lead was
impractical because of venous access or previous
pocket infection. Patients meeting any of these
criteria were included in this study. Patients were
classiﬁed as having either ischemic cardiomyopathy
or nonischemic cardiomyopathy using a combination
of cardiac magnetic resonance imaging, coronary
angiography, and clinical history. Patients were
implanted via a retrograde transaortic approach, as
previously described (10).
Acute hemodynamic response . Acute hemody-
namic response (AHR) was used to assess the imme-
diate response to LVENDO stimulation (23). This
reproducible marker of acute contractility is best
expressed as the change in the maximum rate of LV
pressure, from a baseline control state measured us-
ing a pressure wire positioned within in the LV cavity
(24). Temporary Biventricular endocardial (BiVENDO)
pacing was performed using the patient’s own co-
implant device and either the WiSE-CRT delivery
catheter or a mapping catheter placed within the LV
cavity. During temporary BiVENDO pacing, the A-V
interval was deliberately not optimized. The A-V in-
terval of the co-implant device was used with simul-
taneous V-V stimulation. We assessed how AHR
varied according to measures of electrical latency
including Q-LV (16), Q-LV/QRS ratio, and paced QRS
duration (QRSd). AHR values were obtained in mul-
tiple areas where BiVENDO capture was performed.
Acute responders were deﬁned as those that achieved
a >10% increase in their AHR during LVENDO stimu-
lation at the location chosen to deploy the WiSE-CRT
LV electrode.
Chronic response to CRT (remodel ing) . Patients
were considered echocardiographic responders toCRT if they exhibited a $15% reduction in
end-systolic volume, measured using transthoracic
echocardiography and/or a $5% improvement in LV
ejection fraction (LVEF) 6 months postimplant (25).
STATISTICS. Continuous variables with a Gaussian
distribution were described using mean values 
standard deviation. AHR and electrophysiology data
were tested for normality with the Shapiro-Wilk test.
Signiﬁcance testing on normally distributed paired
data was performed using 2 tailed paired t-tests. Sig-
niﬁcance testing on non-normally distributed paired
data was performed using the Wilcoxon signed-rank
test. Signiﬁcance testing on non-normally distributed
unpaired datawas performed using theMann-Whitney
U test. To account for the clustering of data and mul-
tiple measurements within each patient, a generalized
linear mixed-effect model was applied for all data
points that achieved capture. Multiple data points
recorded from an individual patient are displayed on
the scatterplot using a speciﬁc color marker for each
patient. Lines of best ﬁt with 95% conﬁdence intervals
were shown to aid understanding. Results were
considered signiﬁcant at p < 0.05. Analysis was per-
formed on PASW Statistics 24 (SPSS Inc., Chicago,
Illinois).
TABLE 2 Complications Resulting From Electrode
Deployment (n ¼ 26)
<24 h 1 (3.8%)
Cardiac tamponade 1
>24 h–1 mo 7 (26.9%)
Pseudo-aneurysm 3
Unable to pace left ventricular electrode (1 m) 2
Pocket infection (generator) 1
Pocket hematoma (generator) 1
FIGURE 1 Change in AHR From Baseline During Biventricular
Endocardial Pacing
AHR ¼ acute hemodynamic response; BiVENDO ¼ biventricular
endocardial; LV-dp ¼ maximum rate of left ventricular pressure.
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4RESULTS
PATIENT CHARACTERISTICS. A total of 26 patients
across the 3 centers were implanted with the WiSE-
CRT system using a guided approach (Table 1). Pa-
tients were predominantly male with a mean age of
68.8  8.4 years, mean LVEF 34.2%  7.8% (mini-
mum: 19%; maximum: 51%). The mean QRS duration
was 163.8  26.7 ms. In 92% of patients, the baseline
QRS morphology was a right ventricular paced
rhythm because of the co-implant nature of the WiSE
CRT pacing system. A total of 31% of patients had
experienced AV block requiring pacemaker insertion
before implantation with the WiSE CRT device, 30.8%
of patients had an ischemic etiology, 53% of the pa-
tients had experienced a failed conventional trans-
venous CRT implant, 8% of patients were prior
nonresponders, and 38% of patients had a baseline
LVEF >35%. Patients with a baseline LVEF >35% were
recruited if they required an upgrade to a CRT sys-
tem, but it proved impossible to site a transvenous,
epicardial lead. Some patients had also previously
received transvenous, epicardial CRT and had expe-
rienced a degree of LV remodeling, but had gone on to
develop issues with their LV lead and required an
alternative means of LV stimulation.
PROCEDURAL DETAILS AND SAFETY ISSUES. Procedure
times were 126  65 min with a mean of 3.0  2.6
LVENDO sites tested per patient. A similar complica-
tion rate was observed to that recognized in the
literature (9) (Table 2). Acute complications relating
to electrode implantation (<24 hours) occurred in 1
patient with cardiac tamponade requiring emergency
thoracotomy. The most commonly encountered
adverse events >24 hours to 1 month were compli-
cations arising from femoral arterial access. These
included pseudoaneurysm formation requiring sur-
gical intervention. In 2 cases, it was not possible to
achieve consistent capture of the LVENDO pacing
electrode. In both cases, failure of the screening
procedure to exclude an unsuitable patient was later
conﬁrmed. One patient had comorbid chronicobstructive pulmonary disease with signiﬁcant lung
encroachment affecting the US signal between the
subcutaneous array and endocardial pacing elec-
trode. In the other case, the eventual distance be-
tween the LV pacing electrode and the US array was
too great to achieve consistent capture.
ACUTE HEMODYNAMIC RESPONSE. In 16 of the pa-
tients undergoing guided electrode placement, AHR
was measured intraprocedurally. A signiﬁcant change
in the mean maximum rate of left ventricular pres-
sure was observed during BiVENDO pacing at the target
site (baseline 915.3  211.4 mm Hg/s vs. BiVENDO CRT
1107.4  369.5 mm Hg/s; p ¼ 0.0047) yielding a mean
improvement in AHR of 21.0% (Graph 1). Six-month
follow-up data were available for comparison in 14
of the patients who had undergone electrode
deployment validated by AHR. Twelve patients
experienced a >10% improvement in AHR at the
target site; of these, 92% (n ¼ 11) met the deﬁnition of
an echocardiographic responder, whereas this was
true for only 50% (n ¼ 1) of the patients who failed to
achieve a 10% improvement in AHR at the target site.
Q-LV was measured at the site of endocardial stimu-
lation, as described previously (10), and correlated
against the observed AHR. Delivering BiVENDO pacing
in areas of delayed electrical activation was associ-
ated with greater improvements in AHR (R ¼ 0.356,
p ¼ 0.013; Figure 2A). This correlation remained sig-
niﬁcant, even when accounting for repeated mea-
sures in individual patients using generalized linear
mixed model analysis (mixed model: p ¼ 0.0007). An
even stronger correlation was found between AHR
FIGURE 2 Change in AHR at Various LVENDO Locations vs. Electrophysiological Measures of Electrical Delay
A B
C D
(A) Change in AHR vs. Q-LV. (B) Change in AHR vs. Q-LV/QRS Ratio. (C) Change in AHR vs. Q-LV/QRS ratio >0.5. (D) Change in AHR vs. change in QRSd. Q-LV ¼ the
interval between the onset of the QRS complex on the surface electrocardiogram to the ﬁrst large positive or negative peak of the left ventricular electrogram during a
cardiac cycle; other abbreviations as in Figure 1.
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5and the Q-LV/QRS ratio (R ¼ 0.432, p ¼ 0.003;
Figure 2B). This correlation remained signiﬁcant,
even when repeated measures in individual patients
were accounting for (mixed model: p ¼ 0.0009).
When our cohort was dichotomized into endocardial
locations with an Q-LV/QRS ratio >0.5 and an Q-LV/
QRS ratio <0.5, greater improvements in AHR were
observed when endocardial pacing was delivered at
areas displaying greater electrical latency (14.4 
19.7% vs. 2.3  7.6%, p ¼ 0.01; Figure 2C). Delivering
endocardial pacing in a position that achieved a nar-
rower paced QRSd showed a trend toward greaterimprovements in AHR (R ¼ 0.308, p ¼ 0.03; Graph
2D). This relationship failed to achieve statistical
signiﬁcance when evaluated for repeated measures
(mixed model: p ¼ 0.06).
TISSUE VIABILITY. Scar was identiﬁed using preim-
plant CMR and/or EAM. Seven patients had data
comparing information on tissue viability and AHR,
allowing the analysis of 38 positions. The mean
change in AHR varied depending on whether stimu-
lation was performed in an area of viable or scarred
tissue (3.9%  5.9% vs. þ4.6%  8.8%, p ¼ 0.0456;
Figure 3).
FIGURE 3 Tissue Viability Assessment Comparing Scarred Tissue With
Nonscarred Tissue
Abbreviations as in Figure 1.
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6OPTIMAL ENDOCARDIAL SITE SELECTION. AHR
varied signiﬁcantly depending on the location where
LVENDO stimulation was performed. Inferior and
lateral segments were frequently identiﬁed as the
optimal targets using preprocedural imaging
(Figure 4). The basal inferolateral segment (AmericanFIGURE 4 Target Site Selection vs. Actual Site Achieved
AHA ¼ American Heart Association; LAD ¼ left anterior descending arteHeart Association segment 5) was most frequently
identiﬁed as the optimal target (n ¼ 8). Once a
segment had been selected, it proved technically
feasible to deploy the LVENDO electrode in this area in
92% of patients. In the remaining cases, the electrode
was successfully deployed in an adjacent American
Heart Association segment.
CHRONIC RESPONSE. Six-month follow-up data
were available in 21 of the 26 patients implanted with
a guided approach. Chronic BiVENDO pacing could not
be delivered effectively after implant in 2 patients.
One patient exited the study before follow-up
because of worsening dementia. One patient had
poor echocardiographic windows, rendering assess-
ment of LV performance postimplant impossible, and
follow-up data were not available in 1 patient.
Follow-up data for our cohort are presented in
Table 3. There was a signiﬁcant reduction in QRS
duration with BiVENDO pacing (baseline: 163.8  26.7
ms vs. 6 months: 134.8  25.6 ms; p ¼ 0.002). LV end-
systolic volume was signiﬁcantly reduced at 6 months
(112.7  64.4 at baseline vs. 85  9  52.3 at 6 months;
p < 0.0001). LVEF increased from a baseline of 34.2 
7.8% to 39%  9.8%, p ¼ 0.008). Reverse remodeling
(<15% reduction end-systolic volume) was observed
in 71% patients (n ¼ 15). Ninety percent (n ¼ 19) of
patients met the deﬁnition of echocardiographic
responder (LV end-systolic volume: >15% reduction
and/or >5% EF increase).ry; LCX ¼ circumﬂex artery; RCA ¼ right coronary artery.
TABLE 3 Chronic Response to Guide Implants (n ¼ 21)
Parameter Baseline  SD 6 Mo  SD p Value
QRSd 163.8  26.7 134.8  25.6 0.002
LVESV 112.7  64.4 85.9  52.3 <0.0001
LVEF 34.2  7.8 39  9.8 0.008
LVESV ¼ left ventricular end-systolic volume; SD ¼ standard deviation; other
abbreviation as in Table 1.
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7DISCUSSION
We hypothesized that guided placement of the WiSE-
CRT LV endocardial pacing electrode would achieve
greater improvements in acute markers of contrac-
tility and chronic markers of CRT response. The
principal ﬁndings were as follows.
1. It proved technically feasible to selectively target
and deploy the pacing electrode in a chosen
endocardial segment in almost all cases with a
similar complication rate to that observed in the
published literature (9).
2. The use of a guided approach to facilitate optimal
deployment of theWiSE-CRT LV endocardial pacing
electrode was associated with a reverse remodeling
rate of 71%, whereas 90% of patients met the deﬁ-
nition of an echocardiographic responder.
PERIPROCEDURAL METRICS FOR OPTIMAL ENDOCARDIAL
SITE SELECTION. The optimal LVENDO pacing site dis-
plays large inter- and intrapatient variability. Previ-
ous work identiﬁed that a “lateral area strategy” of
delivering BiVENDO pacing at the lateral wall in a
cohort of nonischemic cardiomyopathy patients,
yielded similar hemodynamic improvements to both
conventional epicardial CRT and echocardio-
graphically guided LVENDO lead placement (10). In our
analysis, infero- and inferolateral segments were
most commonly identiﬁed as representing the
optimal target for WiSE-CRT LV electrode delivery.
Our analysis provides several insights into how best
to determine the optimal LV pacing site. Tissue char-
acterization is fundamental to achieving optimal CRT.
Leyva et al. (26) have previously shown the value of
late gadolinium enhancement CMR to optimizing
epicardial LV lead deployment. Our study conﬁrms
that delivering endocardial pacing in areas of scarred
of ﬁbrotic tissue, prospectively deﬁned using either
CMR or EAM, resulted in a reduction in acute hemo-
dynamics. The mean AHR associated with delivering
BiVENDO CRT in viable tissue showed statistical su-
premacy over stimulating ﬁbrotic tissue and in no pa-
tient was the optimal segment noted to be scarred/
ﬁbrotic. Narrowing of the paced QRSd during acuteBiVENDO pacing showed a trend favoring greater im-
provements in AHR, although this failed to achieve
statistical signiﬁcance when repeated measures in
some patients were accounted for. A strong linear
relationship, however, was identiﬁed between AHR
and both Q-LV and Q-LV/QRSd ratio. As such, targeting
locations that exhibit electrical latency would appear
useful when looking to identify the optimal pacing
site. Endocardial locations with a Q-LV/QRS ratio >0.5
were associated with a 14.3%  19.7% improvement in
AHR. Achieving >10% improvement in AHR during
acute biventricular epicardial CRT has been shown
to be predictive of chronic reverse remodeling
(24), suggesting patients will bemore likely to remodel
if a site with an LV/QRS ratio of 0.5 is selected.
CLINICAL IMPORTANCE. In the current study, the
use of a guided approach to identify and target the
optimal endocardial pacing location resulted in an
impressive reverse remodeling rate of 71% and a
composite echocardiographic response rate of 90%.
These results compare favorably with the recently
published Safety and Performance of Electrodes
Implanted in the Left Ventricle (SELECT-LV) study, in
which indiscriminate deployment of the LV pacing
electrode achieved a remodeling rate of only 52% (9).
This ﬁgure is consistent with the response rate of 40%
to 50% reported in a large meta-analysis of endocar-
dial CRT (27). Our results would suggest that a guided
approach may be able to improve remodeling
response rates in patients receiving BiVENDO CRT.
This is in keeping with previous studies of epicardial
CRT in which guidance increased LV reverse remod-
eling from 55% to 70% (16,17).
STUDY LIMITATIONS. The majority of our cohort
were patients receiving an upgrade from a preexisting
single- or dual-chamber pacing system or in which an
attempt at implanting an LV lead had previously
failed. Echocardiographic response rates amongst
those receiving an upgrade to epicardial CRT have
been found to be comparable to those receiving a de
novo implant; however, the rate of reverse remodel-
ing identiﬁed in our cohort (71%) exceeded the degree
of remodeling expected (28,29). This rate of remod-
eling compares very favorably to that observed in the
SELECT-LV study (9) although, the number of pa-
tients in our analysis whose indication for the WiSE-
CRT LV pacing system was prior nonresponse to
CRT was lower than in SELECT-LV (8% vs. 29%).
Although each center used a combination of pre-
procedural imaging and electroanatomical mapping
to identify the optimal pacing site, the precise guid-
ance protocol varied between centers; however, all
techniques targeted viable tissue that displayed late
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Guided electrode deployment, in which the optimal
LVENDO site is identiﬁed and targeted proved
technically feasible and achieved a higher rate of
volumetric remodeling and echocardiographic
response than has previously been described using
endocardial pacing.
TRANSLATIONAL OUTLOOK: To realize the full
beneﬁts of LVENDO, it is imperative that the optimal
site be identiﬁed and accurately targeted.
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8electrical and or mechanical activation. Finally, the
use of LV reverse remodeling as a surrogate for longer
term CRT response is open to criticism, but it is an
objective and reproducible metric of CRT response.
CONCLUSION
Guided endocardial implants were associated with a
higher degree of chronic LV remodeling compared
with historical nonguided approaches. WiSE-CRT of-
fers a feasible alternative for patients who fail to
derive beneﬁt or who cannot be implanted with a
conventional CRT system. The ability to target the
LV endocardium irrespective of coronary venous
anatomy, without any incidence of phrenic nerve
stimulation is a unique advantage. Targeting late
activating, nonscarred areas of the endocardium may
further improve CRT outcomes in this patient group.
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